Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers

Michael Ouk,Che-Yuan Wu,Jennifer S. Rabin,Jodi D. Edwards,Joel Ramirez,Mario Masellis,Richard H. Swartz,Nathan Herrmann,Krista L. Lanctôt,Sandra E. Black,Walter Swardfager,Alzheimer’s Disease Neuroimaging Initiative

DOI: https://doi.org/10.1016/j.neurobiolaging.2020.12.011

IF: 5.133

2021-04-01

Neurobiology of Aging

Abstract:<p>Some studies suggest that angiotensin II type-1 Receptor Blockers (ARBs) may protect against memory decline more than Angiotensin-Converting Enzyme Inhibitors (ACE-Is), but few have examined possible mechanisms. We assessed longitudinal differences between ARB vs. ACE-I users in global and sub-regional amyloid-β accumulation by ¹⁸F-florbetapir among Alzheimer's Disease Neuroimaging Initiative participants. In cognitively normal older adults (n=142), propensity-weighted linear mixed-effects models showed that ARB vs. ACE-I use was associated with slower amyloid-β accumulation in the cortex, and specifically in the caudal anterior cingulate and precuneus, and in the precentral and postcentral gyri. In amyloid-positive participants with Alzheimer's disease dementia or mild cognitive impairment (n=169), ARB vs. ACE-I use was not associated with different rates of amyloid-β accumulation. Apolipoprotein E (<em>APOE</em>) ε4 carrier status explained some heterogeneity in the different rates of amyloid-β accumulation between users of ARBs vs. ACE-Is in the study. Replicative studies and clinical trials are warranted to confirm potential benefits of ARBs on rates of amyloid-β accumulation in the contexts of Alzheimer's disease prevention and treatment.</p>

neurosciences,geriatrics & gerontology,gerontology